FNAM / Evolutionary Genomics, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-54129 Evolutionary Genomics, Inc. (Exact name of registrant as specifie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Evolutionary Genomics, Inc. (Exact name o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO EVOLUTIONARY GENOMICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO EVOLUTIONARY GENOMICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO EVOLUTIONARY GENOMICS, INC.

Common Stock Subscription Agreement

EXHIBIT 4.2 THE SECURITIES OFFERED INVOLVE A HIGH DEGREE OF RISK AND MAY RESULT IN THE LOSS OF YOUR ENTIRE INVESTMENT. ANY PERSON CONSIDERING THE PURCHASE OF THESE SECURITIES SHOULD CONSULT WITH HIS, HER OR ITS LEGAL, TAX AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN SECURITIES. THE SECURITIES SHOULD ONLY BE PURCHASED BY PERSONS WHO CAN AFFORD TO LOSE ALL OF THEIR INVESTMENT. SUBSCRIPTIO

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 ——————— EVOLUTIONARY GENOMICS, INC. (Exact name of registrant as specified in its charter) ——————— Nevada 000-54129 26-4369698 (State or Other Jurisdict

Preferred Stock Subscription Agreement

EXHIBIT 4.1 THE SECURITIES OFFERED INVOLVE A HIGH DEGREE OF RISK AND MAY RESULT IN THE LOSS OF YOUR ENTIRE INVESTMENT. ANY PERSON CONSIDERING THE PURCHASE OF THESE SECURITIES SHOULD CONSULT WITH HIS, HER OR ITS LEGAL, TAX AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN SECURITIES. THE SECURITIES SHOULD ONLY BE PURCHASED BY PERSONS WHO CAN AFFORD TO LOSE ALL OF THEIR INVESTMENT. SUBSCRIPTIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Evolutionary Genomics, Inc. (Exact name o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO EVOLUTIONARY GENOMICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO EVOLUTIONARY GENOMICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO EVOLUTIONARY GENOMICS, INC.

Annual Report - ANNUAL REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-K ??????? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Evolutionary Genomics, Inc. (Exact name o

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number:

Standard Research Agreement, dated September 15, 2020, by and between the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Madison and EG Crop Science, Inc.

Standard Research Agreement EXHIBIT 10.2

Development and Commercialization Agreement, dated August 19, 2020, by and between EG Crop Science, Inc. and Dole Food Company, Inc.

Development and Commercialization Agreement EXHIBIT 10.1

Quarterly Report - QUARTERLY REPORT

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

- NOTIFICATION OF LATE FILING

Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): Form 10-K Form 20-F Form 11-K ü Form 10-Q Form 10-D Form N-CEN Form N-CSR For Period Ended: June 30, 2020 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q For

Quarterly Report - QUARTERLY REPORT

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

Annual Report - 10-K/A

10-K/A 1 fnam10k.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K/A (Amendment No. 1) ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr

Notice of Termination–Sponsored Research Agreement

Notice of Termination EXHIBIT 10.13

FNAM / Evolutionary Genomics, Inc. 10-K - Annual Report - ANNUAL REPORT

Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Evolutionary Genomics, Inc.

Certificate of Designations, Preferences and Rights of Series A-2 Preferred Stock

EXHIBIT 3.4 EVOLUTIONARY GENOMICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-2 CONVERTIBLE PREFERRED STOCK The undersigned, the Chief Executive Officer of Evolutionary Genomics, Inc., a Nevada corporation (the “Corporation”), in accordance with the provisions of the Nevada Revised Statutes, does hereby certify: That pursuant to the authority conferred upon

FNAM / Evolutionary Genomics, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT

10-Q 1 fnam10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PE

FNAM / Evolutionary Genomics, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT

10-Q 1 fnam10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD

FNAM / Evolutionary Genomics, Inc. 10-Q Quarterly Report QUARTERLY REPORT

10-Q 1 fnam10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD

Wisconsin Crop Innovation Center Service Agreement and Amendment

Wisconsin Crop Innovation Center Service Agreement and Amendment EXHIBIT 10.11

FNAM / Evolutionary Genomics, Inc. ANNUAL REPORT (Annual Report)

Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Evolutionary Genomics, Inc.

State of Colorado Grant Agreement

EX-10.12 3 fnamex10z12.htm STATE OF COLORADO GRANT AGREEMENT EXHIBIT 10.12

FNAM / Evolutionary Genomics, Inc. QUARTERLY REPORT (Quarterly Report)

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commis

Auditor Letter dated October 4, 2018

EX-16.1 2 fnamex16z1.htm AUDITOR LETTER EXHIBIT 16.1 October 4, 2018 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read Evolutionary Genomics, Inc.’s statements included under Item 4.01 of its Form 8-K filed on October 4, 2018 and we agree with such statements concerning our firm. EKS&H LLLP

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

8-K 1 fnam8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2018 ——————— EVOLUTIONARY GENOMICS, INC. (Exact name of registrant as specified in its charter) ——————— Nevada 000-54129 26-

FNAM / Evolutionary Genomics, Inc. QUARTERLY REPORT (Quarterly Report)

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

Other Events

Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2018 ——————— EVOLUTIONARY GENOMICS, INC. (Exact name of registrant as specified in its charter) ——————— Nevada 000-54129 26-4369698 (State or Ot

FNAM / Evolutionary Genomics, Inc. QUARTERLY REPORT (Quarterly Report)

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

FNAM / Evolutionary Genomics, Inc. QUARTERLY REPORT (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Evolutionary Genomics, Inc. (Exact name o

Subsidiaries of Evolutionary Genomics, Inc.

Subsidiaries EXHIBIT 21.1 Subsidiaries Name of Subsidiary Jurisdiction EG Crop Science, Inc. Delaware ICAM Therapeutics, Inc. Delaware

FNAM / Evolutionary Genomics, Inc. QUARTERLY REPORT (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number:

FNAM / Evolutionary Genomics, Inc. QUARTERLY REPORT (Quarterly Report)

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

Amendment 1 to the UM Nguyen Sponsored Research Contract

EXHIBIT 10.9 Agreement Amendment #1 Effective September 16, 2016, this is Amendment # I to the Sponsored Research Contract, fully executed on 3/17/2015, originally signed between the E G Crop Science, Inc. (previously known as Evolutionary Genomics, Inc.), with its principal offices at 1801 Sunset Place, Unit C, Longmont CO 80501 and The Curators of the University of Missouri-Columbia with its pri

Amendment 2 to the UM Zhang Sponsored Research Contract

EX-10.10 3 fnamex10z10.htm AGREEMENT AMENDMENT #2 EXHIBIT 10.10 Agreement Amendment #2 Effective May 20th, 2016, this is Amendment #2 to further amend the Sponsored Research Contract, fully executed on 12124/14 and amended by Amendment #1 on 4/13/16, between the E G Crop Science, Inc. (previously known as Evolutionary Genomics, Inc.),with its principal offices at 1801 Sunset Place, Unit C, Longmon

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2016 o TRANSITION REPORT PURSUANT TO SECT

Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000

Name of Subsidiary Jurisdiction EG Crop Science, Inc. Delaware ICAM Therapeutics, Inc. Delaware

Subsidiaries EXHIBIT 21.1 Subsidiaries Name of Subsidiary Jurisdiction EG Crop Science, Inc. Delaware ICAM Therapeutics, Inc. Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 fnam10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PE

Other Events

Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 8-K ??????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2016 ??????? EVOLUTIONARY GENOMICS, INC. (Exact name of registrant as specified in its charter) ??????? Nevada 000-54129 26-4369698 (State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

Evolutionary Genomics CURRENT REPORT (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 8-K ??????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2016 (February 22, 2016) ??????? EVOLUTIONARY GENOMICS, INC. (Exact name of registrant as specified in its charter) ??????? Nevada 000-54129 41-1

Certificate of Designations, Preferences and Rights of Series A-1 Preferred Stock

EX-3.1 2 fnamex3z1.htm CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A-1 PREFERRED STOCK EXHIBIT 3.1 EVOLUTIONARY GENOMICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-1 CONVERTIBLE PREFERRED STOCK The undersigned, the Chief Executive Officer of Evolutionary Genomics, Inc., a Nevada corporation (the “Corporation”), in accordance with the provi

SUBSCRIPTION AGREEMENT

FORM OF SUBSCRIPTION AGREEMENT EXHIBIT 10.1 THE SECURITIES OFFERED INVOLVE A HIGH DEGREE OF RISK AND MAY RESULT IN THE LOSS OF YOUR ENTIRE INVESTMENT. ANY PERSON CONSIDERING THE PURCHASE OF THESE SECURITIES SHOULD CONSULT WITH HIS, HER OR ITS LEGAL, TAX AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN SECURITIES. THE SECURITIES SHOULD ONLY BE PURCHASED BY PERSONS WHO CAN AFFORD TO LOSE ALL

Evolutionary Genomics AMENDED ANNUAL REPORT (Annual Report)

Amended Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2015 o TRANSITION REPORT PURSUANT TO SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000-54129 Evoluti

State of Colorado Grant Agreement

Exhibit 10.8 CMS #: Fund: 27L0 Unit: AIPU Subunit: AIGR Approp: ECAAB7110 Function: ESCR Object: 5781 Encumbrance #: Grant $: 250,000 Dates: to 5/1/18 STATE OF COLORADO OFFICE OF ECONOMIC DEVELOPMENT AND INTERNATIONAL TRADE Grant Agreement with Evolutionary Genomics, Inc. I TABLE OF CONTENTS 1 1. PARTIES 1 2. EFFECTIVE DATE AND NOTICE OF NONLIABILITY 1 3. RECITALS 1 4. DEFINITIONS 2 5. TERM and EA

Name of Subsidiary Jurisdiction Evolutionary Genomics, Inc. Delaware

EX-21.1 3 fnamex21z1.htm SUBSIDIARIES EXHIBIT 21.1 Subsidiaries Name of Subsidiary Jurisdiction Evolutionary Genomics, Inc. Delaware

Form of Amended and Restated Articles of Incorporation

EX-3.1 2 fnamex3z1.htm AMENDED AND RESTATED ARTICLES OF INCORPORATION EXHIBIT 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF EVOLUTIONARY GENOMICS, INC. Evolutionary Genomics, Inc. (the “Corporation”), formerly known as Fona, Inc., a corporation incorporated under the laws of the state of Nevada on February 4, 2009, hereby amends and restates its Articles of Incorporation, to embody in one

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders

8-K 1 fnam8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2015 (October 19, 2015) ——————— EVOLUTIONARY GENOMICS, INC. (Exact name of registrant as specified in its charter) ———————

Specimen Stock Certificate

EX-4.1 3 fnamex4z1.htm SPECIMEN STOCK CERTIFICATE EXHIBIT 4.1 Number Shares CUSIP 30051F 10 1 EVOLUTIONARY GENOMICS, INC. SEE REVERSE FOR INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA CERTAIN DEFINITIONS AUTHORIZED: 780,000,000 COMMON SHARES, $0.001 PAR VALUE PER SHARE This Certifies that is the owner of Fully Paid and Non-Assessable Common Stock, $0.001 Par Value of EVOLUTIONARY GENOMICS, IN

Subsidiaries of Evolutionary Genomics, Inc., a Nevada corporation

EX-21.1 5 fnamex21z1.htm SUBSIDIARIES Exhibit 21.1 Subsidiaries of Evolutionary Genomics, Inc., a Nevada corporation 1. EG I, LLC, a Colorado LLC 2. Evolutionary Genomics, Inc., a Delaware corporation

SCHUMACHER & ASSOCIATES, INC. Certified Public Accountants 7931 S. Broadway, #314 Littleton, CO 80122 (303) 480-5037 FAX (303) 379-5394 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Auditor Letter EXHIBIT 16.1 SCHUMACHER & ASSOCIATES, INC. Certified Public Accountants 7931 S. Broadway, #314 Littleton, CO 80122 (303) 480-5037 FAX (303) 379-5394 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Dear Commissioners: We have read the statements included under Item 4.01 ?Changes in Registrant?s Certifying Accountant? in the Form 8-K to be filed with the U.S. Securities and E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 8-K ??????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2015 (September 30, 2015) ??????? FONA, INC. (Exact name of registrant as specified in its charter) ??????? Nevada 000-54129 41-1683548 (State or Other J

Fona, Inc. 1026 Anaconda Drive Castle Rock, Colorado 80108 MERGERS PROPOSED?YOUR VOTE IS VERY IMPORTANT

424B3 1 fnam424b.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-203196 Fona, Inc. 1026 Anaconda Drive Castle Rock, Colorado 80108 MERGERS PROPOSED—YOUR VOTE IS VERY IMPORTANT As we previously announced, Fona, Inc. (“Fona”), Evolutionary Genomics, Inc. (“Evolutionary Genomics”) and EG I, LLC (“EG I”) have entered into the Amended and Restated Agreement and Plan of Merger dated Marc

Evolutionary Genomics ESP

Acceleration Request Fona, Inc. 1026 Anaconda Drive Castle Rock, Colorado 80108 (720) 900-8666 September 9, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler Re: Fona, Inc. Registration Statement on Form S-4 Filed April 2, 2015, as amended File No. 333-203196 Dear Mr. Riedler: Pursuant to

As filed with the Securities and Exchange Commission on August 27, 2015

S-4/A As filed with the Securities and Exchange Commission on August 27, 2015 Registration No.

FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS ____, 2015 COMMON STOCK BALLOT

EXHIBIT 99.1 FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS , 2015 COMMON STOCK BALLOT Name of Stockholder(s): (Please Print) Name of Proxy, if applicable: (Please Print) Indicate by an ?x? if proxy has been previously executed and submitted and is revoked hereby: Number of shares: 1. To elect three directors to serve on the Company?s Board of Directors, each to serve until the nex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-

* * * * * * * * * * *

SEC Response Letter July 30, 2015 VIA EDGAR U.S. Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler, Assistant Director Re: Fona, Inc. Amendment No. 1 to Joint Registration Statement and Proxy Statement on Form S-4 Filed July 2, 2015 File No. 333-203196 Dear Mr. Riedler: Fona, Inc. (the “Company”, “Fona”, “it”, “we”

As filed with the Securities and Exchange Commission on July 30, 2015

S-4/A As filed with the Securities and Exchange Commission on July 30, 2015 Registration No.

FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS ____, 2015 COMMON STOCK BALLOT

EX-99.1 4 fnamex99z1.htm FORM OF PROXY CARD EXHIBIT 99.1 FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS , 2015 COMMON STOCK BALLOT Name of Stockholder(s): (Please Print) Name of Proxy, if applicable: (Please Print) Indicate by an “x” if proxy has been previously executed and submitted and is revoked hereby: Number of shares: 1. To elect three directors to serve on the Company’s Boa

Evolutionary Genomics ESP

Response Letter VIA EDGAR July 2, 2015 U.S. Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler, Assistant Director RE: Fona, Inc. Joint Registration Statement and Proxy Statement on Form S-4 Filed April 2, 2015 File No. 333-203196 Dear Mr. Riedler: Fona, Inc. (the ?Company?, ?Fona?, ?it?, ?we?, ?us? or ?our?) hereby

Tennessee State University Agreement

EXHIBIT 10.2 Phenotyping of Cowpea and Common Beans for Evolutionary Genomics Principal Investigator: Dr. Matthew W. Blair (Research Associate Professor) / TSU) Principal Institution: Tennessee State University, Department of Agriculture and Natural Sciences, Lawson Hall, 3500 John A. Merritt Blvd. / Nashville TN Granting Entity: Evolutionary Genomics / Lafayette, CO Principal Grant Contact: Dr. W

Contract for Services University of Missouri

EXHIBIT 10.5 SPONSORED RESEARCH CONTRACT THE CURATORS OF THE UNIVERSITY OF MISSOURI This Contract (the ?Contract?) by and between The Curators of the University of Missouri on behalf of the University of Missouri with its principal offices at 310 Jesse Hall, Office of Sponsored Programs Administration, Columbia, Missouri 65211-1230 (?University?) and Evolutionary Genomics, Inc. with its principal

Bill and Melinda Gates Foundation WO 1

EXHIBIT 10.7 WORK ORDER #1 Ortholog Identification & Validation in Beans & Cowpeas Consultant: Evolutionary Genomics Inc Work Order Effective Date: November 1, 2012 Work Order Expiration Date: August 31, 2014 Master Services Agreement Effective Date: November 1, 2012 Contract #: 22667 This Work Order is agreed pursuant to and made a part of the Master Services Agreement (the ?Agreement?) reference

Fee for Services Agreement University of Missouri

EX-10.4 4 fnamex10z4.htm FEE FOR SERVICE AGREEMENT EXHIBIT 10.4 Fee for Service Agreement This Agreement (the “Agreement”) by and between The Curators of the University of Missouri on behalf of the University of Missouri–Columbia with its principal offices at 310 Jesse Hall, Office of Sponsored Programs Administration, Columbia, Missouri 65211-1230 (“University”) and Evolutionary Genomics, Inc., w

Bill and Melinda Gates Foundation MSA

EX-10.6 6 fnamex10z6.htm MASTER SERVICES AGREEMENT EXHIBIT 10.6 MASTER SERVICES AGREEMENT Consultant: Evolutionary Genomics Inc Contact Name: Walter Messier Address: 1376 Miners Drive Lafayette, CO 80026 UNITED STATES Telephone Numbers: (303) 862-3222 Ext. 302 Email Address: [email protected] Foundation Address: Standard Mail: PO Box 23350, Seattle, WA 98102 Courier: 1432 Elliott Avenue West, S

FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS ____, 2015 COMMON STOCK BALLOT

EX-99.1 10 fnamex99z1.htm FORM OF PROXY CARD EXHIBIT 99.1 FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS , 2015 COMMON STOCK BALLOT Name of Stockholder(s): (Please Print) Name of Proxy, if applicable: (Please Print) Indicate by an “x” if proxy has been previously executed and submitted and is revoked hereby: Number of shares: 1. To elect three directors to serve on the Company’s Bo

Tennessee State University Amendment

EX-10.3 3 fnamex10z3.htm TENNESSEE STATE UNIVERSITY AMENDMENT EXHIBIT 10.3 Amendment to Contract Title: Root Transformation Gene Expression and Nematode Resistance Studies in Common Beans for Evolutionary Genomics Principal Investigator: Dr. Matthew W. Blair (Research Associate Professor) / TSU, Nashville, USA Visiting Scholar: Dr. Xue Renfeng (Subdirector Legumes) / LAAS, Shenyang, China Principa

As filed with the Securities and Exchange Commission on July 2, 2015

S-4/A 1 fnams4.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on July 2, 2015 Registration No. 333-203196 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ——————— Fona, Inc. (Exact name of registrant as specified in its charter) Nevada 6770 41-1683548 (State or othe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000

As filed with the Securities and Exchange Commission on April 2, 2015

S-4 As filed with the Securities and Exchange Commission on April 2, 2015 Registration No.

Equity Incentive Plan

2014 EQUITY INCENTIVE PLAN EXHIBIT 10.1 EG HOLDINGS, INC. 2015 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the EG Holdings, Inc. 2015 Equity Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective directors, officers, employees

AMENDED AND RESTATED ARTICLES OF INCORPORATION EG HOLDINGS, INC.

AMENDED AND RESTATED ARTICLES OF INCORPORATION EXHIBIT 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF EG HOLDINGS, INC. EG Holdings, Inc. (the “Corporation”), formerly known as Fona, Inc., a corporation incorporated under the laws of the state of Nevada on February 4, 2009, hereby amends and restates its Articles of Incorporation, to embody in one document its original articles and the subs

FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS ____, 2015 COMMON STOCK BALLOT

EXHIBIT 99.1 FONA, INC. A NEVADA CORPORATION ANNUAL MEETING OF STOCKHOLDERS , 2015 COMMON STOCK BALLOT Name of Stockholder(s): (Please Print) Name of Proxy, if applicable: (Please Print) Indicate by an ?x? if proxy has been previously executed and submitted and is revoked hereby: Number of shares: 1. To elect three directors to serve on the Company?s Board of Directors, each to serve until the nex

Amended and Restated Agreement and Plan of Merger

AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EXHIBIT 10.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER THIS AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER (the “Agreement”) is made and entered into this 2nd day of March, 2015 (the “Execution Date”), by and among Fona, Inc., a Nevada Corporation (“Parent”), Fona Merger Sub, Inc., a Delaware Corporation (“Sub”), Fona Merger Sub, LLC, a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2014 o TRANSITION REPORT PURSUANT TO SECT

Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commis

FNAM / Evolutionary Genomics, Inc. SC 14F1 - - INFORMATION STATEMENT

SC 14F1 1 fnamsc14f1.htm INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14F-1 THEREUNDER FONA, INC. (Exact name of registrant as specified in its corporate charter) Nevada 000-54129 41-1683548 (State or other jurisdiction of incorporation) (C

SECURITIES PURCHASE AGREEMENT

Securities Purchase Agreement EXHIBIT 99.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of the 1st day of October, 2014, by and among Michael Friess (“Friess”), Sanford Schwartz (“Schwartz”), Nick Boosalis (“Boosalis”), Desfaire, Inc., a Minnesota corporation (“Desfaire”), The Boosalis Group, Inc., a Minnesota corporation (“The Boos

FNAM / Evolutionary Genomics, Inc. / Evolutionary Genomics, Inc. - AMENDMENT NO. 1 Activist Investment

Schedule 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* FONA, INC. (Name of Issuer) Common Stock, $.001 par value. (Title of Class of Securities) 344434 10 5 (CUSIP Number) Steve B. Warnecke 1026 Anaconda Drive Castle Rock, CO 80302 (303) 513-3510 (Name, Address and Telephone Number of Person Authorized to R

JOINT FILING AGREEMENT

EX-99.1 2 fnamex99z1.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, $0.001 par value, of Fona, Inc., and further agree t

Entry into a Material Definitive Agreement

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— Amendment No. 1 FORM 8-K/A ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2014 (October 1, 2014) ——————— FONA, INC. (Exact name of registrant as specified in its charter) ——————— Nevada 000-54129 41-1683

SECURITIES PURCHASE AGREEMENT

Securities Purchase Agreement EXHIBIT 2.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of the 1st day of October, 2014, by and among Michael Friess (“Friess”), Sanford Schwartz (“Schwartz”), Nick Boosalis (“Boosalis”), Desfaire, Inc., a Minnesota corporation (“Desfaire”), The Boosalis Group, Inc., a Minnesota corporation (“The Boosa

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2014 (October 1, 2014) ——————— FONA, INC. (Exact name of registrant as specified in its charter) ——————— Nevada 000-54129 41-1683548 (State or Other Jurisdi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

FNAM / Evolutionary Genomics, Inc. NT 10-Q - - NOTIFICATION OF LATE FILING

Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SECURITIES PURCHASE AGREEMENT

Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of the 6th day of June, 2014, by and among Michael Friess (“Friess”), Sanford Schwartz (“Schwartz”, together with Friess, each a “Seller” and collectively, the “Sellers”) and Evolutionary Genomics, Inc. (the “Buyer”). W I T N E S S E T H: WHEREAS, Sellers own, in the aggregat

SECURITIES PURCHASE OPTION AGREEMENT

Exhibit 99.3 SECURITIES PURCHASE OPTION AGREEMENT This SECURITIES PURCHASE OPTION AGREEMENT (the “Agreement”) is made and entered into as of the 6th day of June, 2014, by and among Nick Boosalis, a resident of the state of Minnesota (“Boosalis”), Desfaire, Inc., a Minnesota corporation (“Desfaire”), The Boosalis Group, Inc., a Minnesota corporation (“The Boosalis Group”, together with Boosalis and

JOINT FILING AGREEMENT

EX-99.1 2 sc13d0614ex99ifona.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, $0.001 par value, of Fona, Inc., and further

FNAM / Evolutionary Genomics, Inc. / Evolutionary Genomics, Inc. - SCHEDULE 13D Activist Investment

SC 13D 1 sc13d0614evolutionaryfona.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* FONA, INC. (Name of Issuer) Common Stock, $.001 par value. (Title of Class of Securities) 344434 10 5 (CUSIP Number) Michael Friess 2575 Pearl Street, Suite 225, Boulder, Colorado 80302 (303) 499-6000 (Name, Address a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2014 (June 6, 2014) FONA, INC. (Exact Name of Registrant Specified in Charter) Nevada 000-54129 41-1683548 (State or Other Jurisdiction of Incorporation) (Commission File Num

AGREEMENT AND PLAN OF MERGER

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (the “Agreement”) is made and entered into this 6th day of June, 2014 (the “Execution Date”), by and among Fona, Inc., a Nevada Corporation (“Parent”), Fona Merger Sub, Inc., a Delaware Corporation (“Sub”), Fona Merger Sub, LLC, a Colorado limited liability company (“Sub LLC”, together with Sub and Parent, collectively the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2013 o TRANSITION REPORT PURSUANT TO SECT

Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000

- NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: December 31, 2013 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q Transition R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 33-4

- LATE FILING NOTIFICATION FORM

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

- NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): Form 10-K Form 20-F Form 11-K ü Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: March 31, 2013 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q Transition Repo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2012 o TRANSITION REPORT PURSUANT TO SECT

Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-K ——————— þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 000

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No.1

Form 10Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No.1 (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No.1

Form 10Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No.1 (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No.1 (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 33

- NOTIFICATION OF LATE FILING

Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

-

Fona, Inc. 2575 Pearl St. Ste. 220 Boulder, CO 80302 February 15, 2013 VIA E-Mail Ms. Linda Cvrkel Securities and Exchange Commission Division of Corporate Finance 100 F Street NE Washington, DC 20549 RE: Fona, Inc. Form 10-K, for the year ended December 31, 2011 Filed March 30, 2012 File No.: 000-54129 Ladies and Gentlemen: Fona, Inc. (the “Company”) responds to the comments raised by the staff o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K /A Amendment No.1

Amendment No. 1 to Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K /A Amendment No.1 þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number:

-

Fona, Inc Fona, Inc. 2575 Pearl St. Ste. 220 Boulder, CO 80302 November 1, 2012 VIA E-Mail Ms. Linda Cvrkel Securities and Exchange Commission Division of Corporate Finance 100 F Street NE Washington, DC 20549 RE: Fona, Inc. Form 10-K, for the year ended December 31, 2011 Filed March 30, 2012 File No.: 000-54129 Ladies and Gentlemen: Fona, Inc. (the “Company”) responds to the comments raised by th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 33-45904C FONA, INC.